n a blow to Alexion Pharmaceuticals (ALXN), a Canadian government agency ordered the drug maker to lower the price of a rare disease medicine and reimburse the government for “excessive” pricing.

The ruling by the Patented Medicine Prices Review Board follows a long-running struggle that began after the drug maker three years ago refused to lower its price for Soliris, which, depending upon the disease, costs either US$383,000 or $585,000 per patient. The government agency also asked Alexion to repay sales generated by the drug from 2012 through the first half of 2014.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.